FindTrial
Sign In

Development and delivery of personalized 3D-printed drugs to improve treatment adherence in children with rare diseases.

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519378-37-00
Acronym
IMPRIMIDO
Enrollment
14
Registered
2025-03-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

biotinidasa deficit, Metilcrotonilglicinuria

Brief summary

visual scale and in the collection of subjective symptoms reported by the patient.

Detailed description

Determination of organic acids, plasma biotin levels

Interventions

DRUGBIOTIN
DRUGMedebiotin Fuerte solución inyectable
DRUGMedebiotín Fuerte Comprimidos

Sponsors

Fundacion Publica Galega Instituto De Investigacion Sanitaria De Santiago De Compostela
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
visual scale and in the collection of subjective symptoms reported by the patient.—

Secondary

MeasureTime frame
Determination of organic acids, plasma biotin levels—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026